A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

February 29, 2008

Conditions
Lung CancerNon-Small Cell Lung Cancer
Interventions
DRUG

ABT-751

200mg ABT-751 daily for 14 days every 21 days

DRUG

Placebo

Placebo daily for 14 days every 21 days

DRUG

Docetaxel

Standard Docetaxel every 21 days

Trial Locations (32)

14215

Site Ref # / Investigator 3569, Buffalo

37920

Site Ref # / Investigator 3549, Knoxville

38555

Site Ref # / Investigator 3551, Crossville

44195

Site Ref # / Investigator 3511, Cleveland

44266

Site Ref # / Investigator 5237, Ravenna

54476

Site Ref # / Investigator 3510, Weston

60031

Site Ref # / Investigator 3512, Gurnee

91505

Site Ref # / Investigator 4771, Burbank

92270

Site Ref # / Investigator 3567, Rancho Mirage

35294-3300

Site Ref # / Investigator 3572, Birmingham

92868-3298

Site Ref # / Investigator 3574, Orange

07601

Site Ref # / Investigator 3565, Hackensack

37232-6307

Site Ref # / Investigator 3571, Nashville

B1P 1P3

Site Ref # / Investigator 3563, Sydney

L4M 6M2

Site Ref # / Investigator 3559, Barrie

P3E 5J1

Site Ref # / Investigator 3561, Greater Sudbury

J4V 2H1

Site Ref # / Investigator 3560, Greenfield Park

H2W 1S6

Site Ref # / Investigator 3562, Montreal

H3T 1E2

Site Ref # / Investigator 2222, Montreal

S4T 7T1

Site Ref # / Investigator 3558, Regina

Unknown

Site Ref # / Investigator 5097, Cork

Site Ref # / Investigator 4971, Dublin

Site Ref # / Investigator 4986, Dublin

Site Ref # / Investigator 4999, Dublin

Site Ref # / Investigator 5158, Dublin

BT9 7AB

Site Ref # / Investigator 5259, Belfast

ME16 9QQ

Site Ref # / Investigator 5270, East Barming

EH42XU

Site Ref # / Investigator 5271, Edinburgh

G12 0YN

Site Ref # / Investigator 5017, Glasgow

HU8 9HE

Site Ref # / Investigator 5274, Hull

GU2 7XX

Site Ref # / Investigator 5273, Surrey

SM2 5NG

Site Ref # / Investigator 5268, Surrey

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00354562 - A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter